We are live on ! Find out more
SGTX

Sigilon Therapeutics, Inc. Common Stock

Delisted

SGTX was delisted on the 10th of August, 2023.

50 hedge funds and large institutions have $52.2M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $84K | Put options by funds: $48K

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

11% more funds holding

Funds holding: 4550 (+5)

52% less capital invested

Capital invested by funds: $109M → $52.2M (-$56.8M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
50
Holders Change
+5
Holders Change %
+11.11%
% of All Funds
0.77%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
14
Increased
16
Reduced
10
Closed
9
Calls
$84K
Puts
$48K
Net Calls
+$36K
Net Calls Change
+$282K
Name Holding Trade Value Shares
Change
Change in
Stake
WP
51
Woodline Partners
California
-$193K -2,631 Closed
Squarepoint
52
Squarepoint
New York
-$120K -1,633 Closed
CSS
53
Cubist Systematic Strategies
Connecticut
-$107K -1,463 Closed
Jane Street
54
Jane Street
New York
-$77K -1,049 Closed
PHK
55
Point72 Hong Kong
Hong Kong
-$4K -49 Closed
Toronto Dominion Bank
56
Toronto Dominion Bank
Ontario, Canada
+$57 +1 New
SPA
57
Shore Point Advisors
New Jersey
+$114 +2 New

SGTX Hedge Fund Activity: Q4 2021 in Review

50 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q4 2021, worth a combined $52.2M — down 52% from $109M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SGTX positions and 9 closed out — a net gain of 5 holders — while 16 added to existing stakes and 10 trimmed.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $876K. The largest seller was American Century Companies, exiting entirely with an estimated $2.03M sold.

  • 50 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q4 2021, up from 45 in Q3 2021.
  • Funds reported $52.2M of Sigilon Therapeutics, Inc. Common Stock stock for Q4 2021, down 52% quarter-over-quarter.
  • 14 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +5 holders.
  • The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q4 2021 was Bridgeway Capital Management, an estimated $876K added.
  • The largest Sigilon Therapeutics, Inc. Common Stock seller in Q4 2021 was American Century Companies, an estimated $2.03M sold.

Based on aggregated 13F filings for Q4 2021.